6.47
0.00
(0.00%)
At close: January 16 at 4:00:00 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jul 2024) | Next Qtr. (Oct 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 3 |
| Avg. Estimate | -0.03 | -0.02 | -0.11 | -0.12 |
| Low Estimate | -0.03 | -0.03 | -0.11 | -0.13 |
| High Estimate | -0.03 | -0.02 | -0.1 | -0.1 |
| Year Ago EPS | -0.03 | -0.04 | -0.13 | -0.11 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jul 2024) | Next Qtr. (Oct 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 3 | 2 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| Currency in USD | 7/31/2023 | 10/31/2023 | 1/31/2024 | 4/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.02 | -0.02 | -0.03 | -0.03 |
| EPS Actual | -0.03 | -0.04 | -0.03 | -0.03 |
| Difference | -0.01 | -0.02 | 0 | 0 |
| Surprise % | -50.00% | -100.00% | 0.00% | 0.00% |
EPS Trend
| Currency in USD | Current Qtr. (Jul 2024) | Next Qtr. (Oct 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.03 | -0.02 | -0.11 | -0.12 |
| 7 Days Ago | -0.03 | -0.02 | -0.11 | -0.12 |
| 30 Days Ago | -0.03 | -0.03 | -0.09 | -0.12 |
| 60 Days Ago | -0.03 | -0.03 | -0.12 | -0.13 |
| 90 Days Ago | -0.03 | -0.03 | -0.13 | -0.13 |
EPS Revisions
| Currency in USD | Current Qtr. (Jul 2024) | Next Qtr. (Oct 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| SVA | 0.00% | 50.00% | 15.40% | -9.10% |
| S&P 500 | 9.90% | 11.00% | 14.01% | 13.54% |
Upgrades & Downgrades
| Upgrade | Morgan Stanley: Overweight | 3/20/2014 |
| Maintains | Aegis Capital: Buy | 11/13/2013 |
| Upgrade | Aegis Capital: Hold to Buy | 8/15/2013 |
| Upgrade | Morgan Stanley: Underperform to Equal-Weight | 5/15/2013 |
| Maintains | Aegis Capital: Hold | 3/14/2013 |
| Initiated | Aegis Capital: Hold | 12/12/2012 |
Related Tickers
WINTW WINDTREE THERAPEUTICS INC C/WTS
0.0090
+1,400.00%
9926.HK Akeso, Inc.
62.600
+2.79%
SVA.TO Sernova Corp.
0.2000
+2.56%
NXTC NextCure, Inc.
0.8230
-4.08%
GTBP GT Biopharma, Inc.
2.4200
+1.68%
VTVT vTv Therapeutics Inc.
13.99
-0.57%
IFRX InflaRx N.V.
2.3400
-1.27%
ALEC Alector, Inc.
1.7900
-1.10%
IDYA IDEAYA Biosciences, Inc.
23.62
+1.42%
HOOK HOOKIPA Pharma Inc.
2.1700
+6.37%